Mega Lifesciences Public Company (MEGA) Fair Value & Analysis
Healthcare · TH · Market cap 30.7B THB
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Share price −1.4% over the past month.
Price vs Fair Value (12 months)
12‑month range 22.94 THB – 37.49 THB · fair‑value band 36.18 THB – 60.31 THB · the 34.25 THB price screens below the 48.25 THB fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Mega Lifesciences Public Company (MEGA) currently trades at 34.25 THB, while our model-based Fair Value estimate is 48.25 THB — implying the stock looks roughly 40.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Mega Lifesciences Public Company generated revenue of 14.2B THB at a net margin of 13.5%. Revenue grew 0.1% year over year. It earns a return on equity of 19.0%. The balance sheet holds a net cash position of 3.5B THB. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. The company operates through three segments: Brands, Distribution, and Original Equipment Manufacture. It offers wellness and nutrition products, including medical and sports nutrition, general well-being, vitamins, probiotics, herbal medicines, and cough and cold medicines, as well as hair, kid's, men's, and women's care products; and various health concerns products, such as allergy, bone and joint, gut, liver, diabetic, eye, heart, brain, sleep and anxiety, pain, and skin care, as well as blood circulation and memory. The company also provides prescription medicines for anti-allergic, anti-infective, cardiovascular system, central nervous system, dermatology, diabetes, gastrointestinal, gynecology, nephrology, oncology, ophthalmology, ort…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Mega Lifesciences Public Company reported revenue of 14.1B THB in FY2025 versus 14.1B THB in FY2021, a compound +0.0%/yr. Reported net income was 1.9B THB in FY2025, compounding −0.5%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Mega Lifesciences Public Company (MEGA) undervalued?
What is the fair value of MEGA?
What is the quality score of MEGA?
What is the revenue of Mega Lifesciences Public Company (MEGA)?
What is the net profit margin of MEGA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.